We are live on ! Find out more
RDHL

Redhill Biopharma
RDHL

21 hedge funds and large institutions have $30.5M invested in Redhill Biopharma in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 21 → 21 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

8% less capital invested

Capital invested by funds: $33.1M → $30.5M (-$2.56M)

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

Holders
21
Holders Change
–
Holders Change %
0%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FM
Family Management
New York
+$20.9K
2
Creative Planning
Creative Planning
Kansas
+$10.5K
3
Deutsche Bank
Deutsche Bank
Germany
+$10.5K

Top Sellers

Rank Fund Capital Flow
1
NC
Nexthera Capital
New York
-$309K
2
FAM
Fred Alger Management
New York
-$178K
3
BC
Broadfin Capital
New York
-$126K
4
BHB
Bank Hapoalim BM
Israel
-$94.2K
5
Morgan Stanley
Morgan Stanley
New York
-$94.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$10M -$126K -12 -1%
O
2
OrbiMed
New York
$6.92M – – –
VAM
3
Visium Asset Management
New York
$6.13M – – –
MMH
4
Menora Mivtachim Holdings
Israel
$3.01M – – –
SM
5
Sabby Management
Florida
$1.92M -$31.4K -3 -2%
CS
6
Candriam SCA
Luxembourg
$868K – – –
BHB
7
Bank Hapoalim BM
Israel
$561K -$94.2K -9 -16%
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$259K – – –
FM
9
Family Management
New York
$202K +$20.9K +2 +13%
FAM
10
Fred Alger Management
New York
$190K -$178K -17 -52%
VanEck Associates
11
VanEck Associates
New York
$116K – – –
PVH
12
Psagot Value Holdings
Israel
$69K -$10.5K -1 -14%
Morgan Stanley
13
Morgan Stanley
New York
$68K -$94.2K -9 -60%
Wells Fargo
14
Wells Fargo
California
$49K – – –
MMG
15
Monetary Management Group
Missouri
$37K -$10.5K -1 -25%
UBS Group
16
UBS Group
Switzerland
$25K – – –
Bank of America
17
Bank of America
North Carolina
$12K – – –
Creative Planning
18
Creative Planning
Kansas
$12K +$10.5K +1 New
Deutsche Bank
19
Deutsche Bank
Germany
$10K +$10.5K +1 New
WA
20
WFG Advisors
Texas
$9K – – –
AIM
21
Acrospire Investment Management
Illinois
$9K +$10.5K +1 New
TWA
22
TCI Wealth Advisors
Arizona
$5K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$4K – – –
NC
24
Nexthera Capital
New York
– -$309K -24 Closed
Walleye Trading
25
Walleye Trading
New York
– -$44K -3 Closed
1
2

RDHL Hedge Fund Activity: Q1 2016 in Review

21 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q1 2016, worth a combined $30.5M — down 7.7% from $33.1M a quarter earlier.

Fund positioning in RDHL was balanced in Q1 2016: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 7 trimmed.

The largest buyer was Family Management, adding an estimated $20.9K. The largest seller was Nexthera Capital, exiting entirely with an estimated $309K sold.

  • 21 institutional investors held Redhill Biopharma (RDHL) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $30.5M of Redhill Biopharma stock for Q1 2016, down 7.7% quarter-over-quarter.
  • 3 funds opened new Redhill Biopharma positions in Q1 2016 and 3 closed out, a net change of 0 holders.
  • The largest Redhill Biopharma buyer in Q1 2016 was Family Management, an estimated $20.9K added.
  • The largest Redhill Biopharma seller in Q1 2016 was Nexthera Capital, an estimated $309K sold.

Based on aggregated 13F filings for Q1 2016.